Clover Health Investments, Corp. filings document the company’s Medicare Advantage insurance business, physician enablement technology, operating results, governance, and material events. Recent 8-K reports furnish earnings releases, guidance updates, Medicare Advantage enrollment information, Regulation FD presentations, and supplemental shareholder Q&A materials related to financial performance and business priorities.
Proxy materials cover annual meeting matters, board and governance disclosures, executive compensation, equity awards, and related stockholder voting items. Other current reports document officer transitions, principal financial and accounting officer appointments, compensatory arrangements, and formal disclosures connected to the company’s remote-first corporate structure and public-company reporting obligations.
Clover Health Investments, Corp. (CLOV) officer Jamie Reynoso intends to sell 2,006 common shares, with an aggregate market value of $9,227.60 and an approximate sale date of October 7, 2026. Morgan Stanley Smith Barney LLC is identified as the broker. The shares are described as Restricted Stock Units acquired from the issuer.
Clover Health Investments, Corp. (CLOV) reported that Jamie L. Reynoso, CEO, Medicare Advantage, sold 8,750 Class A common shares at $4.42 per share on October 5, 2026, leaving 2,794,696 shares directly held. The shares were required to be sold to cover tax withholding tied to the October 3, 2026 quarterly vesting of 6.25% of Reynoso’s restricted stock units. The issuer’s plan required the sell-to-cover transaction, which the footnote says was not discretionary. The transaction was reported under a Rule 10b5-1 plan.
Clover Health Investments, Corp. (CLOV) is named as issuer in a notice that Jamie Reynoso, an officer, proposes to sell 8,706 Class A common shares, with an aggregate market value of $40,744.08. The notice gives an approximate sale date of October 5, 2026, and names Morgan Stanley Smith Barney LLC as broker. It says the sale is a sell-to-cover transaction for tax withholding on restricted stock unit vesting and settlement, not a discretionary sale.
Clover Health Investments, Corp. director Brian James Miller was granted a time-based restricted stock unit award representing 12,481 shares of Class A common stock on September 30, 2026. The award will vest in full on the first anniversary of that date, subject to his continued service as a member of the company's board through the vesting date. The reported post-transaction amount is 12,481 shares underlying the award.
Clover Health Investments, Corp. director Robert G. Torricelli received a time-based restricted stock unit award covering 12,481 shares of Class A common stock on September 30, 2026. The award vests in full on the first anniversary of that date, subject to his continued service as a board member through the vesting date. His reported direct position following the award was 186,897 shares.
Clover Health Investments’ chief executive officer Andrew Toy sold 318,806 Class A shares on October 1, 2026, at a weighted average price of $4.19 per share; sales ranged from $4.18 to $4.21. The sale covered tax withholding tied to quarterly vesting of restricted stock units. The sales were issuer-mandated, not discretionary, and were made pursuant to a Rule 10b5-1 plan. Toy held 9,140,510 Class A shares directly afterward.
Clover Health Investments, Corp. (CLOV) director Robert G. Torricelli reported 174,416 shares on September 22, 2026: 141,253 shares held directly and 33,163 shares underlying a time-based restricted stock unit award. The RSUs vest in full on the first anniversary of April 1, 2026, subject to his continued service as a board member through that vesting date.
Clover Health Investments, Corp. reports that Andrew Toy, an Officer, proposes to sell 309,558 shares of Class A Common Stock. The notice describes the sale as a sell-to-cover transaction to meet tax withholding obligations tied to restricted stock unit vesting and settlement, not as a discretionary transaction. It also lists three sales under a 10b5-1 plan during July and August 2026.
Clover Health Investments, Corp. appointed Senator Robert G. Torricelli as a Class I director and Dr. Brian J. Miller as a Class III director on September 22, 2026, filling two vacancies and bringing the Board to nine directors. Torricelli joins the Audit Committee, and Miller joins the Clinical Committee. Each will receive a pro rata portion of the applicable 2026 annual retainer and a restricted stock unit award with a $200,000 value, prorated based on days of service through December 31, 2026, using 365 days as the denominator. The amendment corrects the accompanying press release title and states that no other original disclosures are amended or updated.